Low-cost Humira competitors hit the U.S. market

The rundown: India's Biocon Biologics launched a biosimilar of Humira in the U.S. called Hulio on Monday, Reuters reports.

• California-based Coherus Biosciences also launched a version called Yusimry. Last month, the company announced it would partner with Mark Cuban's Cost Plus Drug Company to offer the drug to customers at a price of $569.27, plus dispensing and shipping fees starting this month.
• Germany's Fresenius and Boehringer Ingelheim, Switzerland-based Sandoz and South Korea-based Celltrion Healthcare also launched Humira biosimilars.

Yes, but: As Axios previously reported, PBMs may be slow to adopt the cheaper versions of the drug.